Acadia Healthcare Company, Inc. (ACHC)
| Market Cap | 3.49B +136.4% |
| Revenue (ttm) | 3.41B +4.5% |
| Net Income | -1.13B |
| EPS | -12.45 |
| Shares Out | 92.97M |
| PE Ratio | n/a |
| Forward PE | 18.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,692,401 |
| Open | 37.85 |
| Previous Close | 37.94 |
| Day's Range | 37.15 - 38.15 |
| 52-Week Range | 11.43 - 39.70 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 39.07 (+3.94%) |
| Earnings Date | Nov 4, 2026 |
About ACHC
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ACHC stock is "Buy." The 12-month stock price target is $39.07, which is an increase of 3.94% from the latest price.
News
Acadia Healthcare Company Transcript: 2026 Stephens Annual Investment Conference | NASH2026
2026 brought stronger operating execution, three consecutive full-year guidance increases, and improving balance-sheet performance. Sixteen new facilities are expected to contribute $60 million of incremental EBITDA in 2027, with legacy capacity, continuum expansion, and disciplined investment supporting further growth.
Acadia Healthcare Company Transcript: UBS Global Healthcare Conference
First 9–10 months exceeded internal expectations, with 2027 momentum supported by a projected $60 million incremental EBITDA contribution from newer facilities. Acute volumes and occupancy improved, while disciplined facility expansion, revenue-cycle progress and stable labor support growth.
Acadia Healthcare price target raised to $46 from $32 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Acadia Healthcare (ACHC) to $46 from $32 and keeps a Buy rating on the shares.
Acadia Healthcare price target raised to $41 from $31 at RBC Capital
RBC Capital raised the firm’s price target on Acadia Healthcare (ACHC) to $41 from $31 and keeps an Outperform rating on the shares. The firm is positive on the company’s…
Acadia Healthcare price target raised to $45 from $41 at UBS
UBS analyst AJ Rice raised the firm’s price target on Acadia Healthcare (ACHC) to $45 from $41 and keeps a Buy rating on the shares.
Acadia Healthcare price target raised to $39 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst Sarah James raised the firm’s price target on Acadia Healthcare (ACHC) to $39 from $30 and keeps a Neutral rating on the shares. Acadia Healthcare delivered a…
Acadia Healthcare price target raised to $40 from $36 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Acadia Healthcare (ACHC) to $40 from $36 and keeps a Buy rating on the shares. The firm updated its…
Acadia Healthcare price target raised to $40 from $36 at TD Cowen
TD Cowen raised the firm’s price target on Acadia Healthcare (ACHC) to $40 from $36 and keeps a Buy rating on the shares. The firm updated its model following Q3…
Acadia Healthcare price target raised to $36 from $31 at Mizuho
Mizuho raised the firm’s price target on Acadia Healthcare (ACHC) to $36 from $31 and keeps a Neutral rating on the shares.
Acadia Healthcare price target raised to $41 from $39 at Guggenheim
Guggenheim raised the firm’s price target on Acadia Healthcare (ACHC) to $41 from $39 and keeps a Buy rating on the shares.
Acadia Healthcare Company Earnings Call Transcript: Q3 2026
Q3 revenue rose 5.1% YoY and adjusted EBITDA exceeded expectations, prompting higher FY26 guidance. Management expects $60M of incremental adjusted EBITDA from facility cohorts in 2027; potential supplemental payments remain excluded from guidance.
Acadia Healthcare Company Earnings release: Q3 2026
Acadia Healthcare Company released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Acadia Healthcare Company Quarterly report: Q3 2026
Acadia Healthcare Company has published its Q3 2026 quarterly earnings report on November 5, 2026.
Acadia Healthcare Company Slides: Q3 2026
Acadia Healthcare Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Acadia Healthcare price target raised to $35 from $32 at Barclays
Barclays raised the firm’s price target on Acadia Healthcare (ACHC) to $35 from $32 and keeps an Equal Weight rating on the shares.
Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2026. Third Qua...
Acadia Healthcare to Participate in November Investor Conferences
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two investor conferences in November. On Monday, November 9, 2026,...
Did Acadia Healthcare Company, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2026 results on Wednesday, November 4, 2026, after the close of ...
Acadia Healthcare downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Acadia Healthcare (ACHC) to Outperform from Strong Buy with a $39 price target The reflects limited near-term visibility into PLGL accrual dynamics rather than reduced confide...
Acadia Healthcare downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Acadia Healthcare (ACHC) to Outperform from Strong Buy with an unchanged price target of $39.
Acadia Healthcare Provides Notice of Proposed Derivative Action Settlement
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) issues the below summary notice of proposed settlement as provided for in the September 1, ...
Acadia Healthcare price target raised to $33 from $30 at Leerink
Leerink analyst Whit Mayo raised the firm’s price target on Acadia Healthcare (ACHC) to $33 from $30 and keeps a Market Perform rating on the shares. The firm is fine…
Acadia Healthcare Company Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Strong demand and stable revenue trends are driving growth, with management confident in achieving $200 million incremental EBITDA from new beds and operational improvements. Facility ramp-up, disciplined cost management, and stable labor conditions support positive momentum.
Acadia Healthcare to Participate in 2026 Jefferies Healthcare Services and Technology Conference
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in a fireside chat at the 2026 Jefferies Healthcare Services and Tech...